査読有
doi:10.1007/s00432-025-06085-1
PubMed No.:39875560
2023 Impact Factor:2.7
種類:原著
誌名:Journal of cancer research and clinical oncology
発行年月:2025年1月
巻号頁:151: 52, 2025
論題:Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
著者:Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo